Heard about a mab that was addressing inflammation

Quote:

---

Heard about a mab that was addressing inflammation leading to Alzheimers -- at Brigham & Womens -- on NPR today -- any thoughts on this one

---

Foralumab targets and reduces CD-3 on T cells which lowers overreactive microglia and increases Tregs. It also reduces inflammation. So it acts as an immunosuppressor. Any doctor prescribing it should monitor for infections and it would be counterindicated for anyone with cancer.

Leronlimab would return microglia to a normal state and reduce inflammation via reduction of inflammatory cytokines. It's an immunomodulator not an immunosuppressor.

The current results for Foralumab in an expanded access multiple sclerosis study -

Quote:

---

According to a recent announcement, the FDA has allowed an expanded access (EA) program assessing intranasal foralumab (Tiziana Life Sciences) non-active secondary progressive multiple sclerosis (na-SPMS) to increase from 10 patients to a total of 30 patients.1 The available data from the currently enrolled patients are the first to combine PET imaging with a novel ligand, immune-biomarkers, clinical measures and comprehensive safety data end points in patients treated with long-term intranasal foralumab.

As of April 2024, 2 of the 10 participating patients were dosed for more than 1 year and 8 additional patients were dosed for 6 months, all with no reports of serious adverse effects. All participants were either stabilized or displayed improvement on foralumab, and none declined in key clinical measures. Investigators noted that 70% of these participants did not report any measurable improvement in fatigue while on treatment with foralumab.

In the study, a voxel-by-voxel z-score mapping approaches was used and sum of z-scores in voxels with z-values of more than 2 were calculated. In addition to the 6 patients, the study also included 2 patients with na-SPMS with PIRA who underwent a test and a retest (F-18)PBR06-PET scan. In the foralumab-treated group, white matter z-scores were reduced by 26%-36% at 3 and 6 months, which was at least 4-5-times higher compared to the 6% variability observed in the test-retest group (PET effect size estimate at 3 months, 1.4).3
https://www.neurologylive.com/view/fda-allows...ss-program

---